search
Back to results

Study of Bile Acids in Patients With Peroxisomal Disorders

Primary Purpose

Infantile Refsum's Disease, Zellweger Syndrome, Bifunctional Enzyme Deficiency

Status
Terminated
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
chenodeoxycholic acid
cholic acid
ursodiol
Sponsored by
University of Cincinnati
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infantile Refsum's Disease focused on measuring Zellweger syndrome, adrenoleukodystrophy, bifunctional enzyme deficiency, inborn errors of metabolism, infantile Refsum's disease, peroxisomal disorders, pseudo-Zellweger syndrome, rare disease, sphingolipidoses

Eligibility Criteria

undefined - 5 Years (Child)All SexesDoes not accept healthy volunteers

Biochemically proven peroxisomal disorder, including: Zellweger syndrome Pseudo-Zellweger syndrome Neonatal adrenoleukodystrophy Bifunctional enzyme deficiency Infantile Refsum's disease

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    October 18, 1999
    Last Updated
    March 24, 2015
    Sponsor
    University of Cincinnati
    Collaborators
    Children's Hospital Medical Center, Cincinnati
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00004442
    Brief Title
    Study of Bile Acids in Patients With Peroxisomal Disorders
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2000
    Overall Recruitment Status
    Terminated
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    April 1999 (undefined)

    3. Sponsor/Collaborators

    Name of the Sponsor
    University of Cincinnati
    Collaborators
    Children's Hospital Medical Center, Cincinnati

    4. Oversight

    5. Study Description

    Brief Summary
    OBJECTIVES: I. Determine the effectiveness of oral bile acid therapy with cholic acid, chenodeoxycholic acid, and ursodeoxycholic acid in patients with peroxisomal disorders involving impaired primary bile acid synthesis. II. Determine whether suppression of synthesis of atypical bile acids and enrichment of bile acid pool with this regimen is effective in treating this patient population and improving quality of life.
    Detailed Description
    PROTOCOL OUTLINE: Patients receive oral cholic acid and oral chenodeoxycholic acid on day 1. On day 4, patients receive oral cholic and ursodeoxycholic acids. Patients are assessed at 3 and 6 months for liver function response, neurologic status, and nutritional status. Patients receive treatment until disease progression or unacceptable toxic effects are observed. Completion date provided represents the completion date of the grant per OOPD records

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Infantile Refsum's Disease, Zellweger Syndrome, Bifunctional Enzyme Deficiency, Adrenoleukodystrophy
    Keywords
    Zellweger syndrome, adrenoleukodystrophy, bifunctional enzyme deficiency, inborn errors of metabolism, infantile Refsum's disease, peroxisomal disorders, pseudo-Zellweger syndrome, rare disease, sphingolipidoses

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Enrollment
    25 (Anticipated)

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    chenodeoxycholic acid
    Intervention Type
    Drug
    Intervention Name(s)
    cholic acid
    Intervention Type
    Drug
    Intervention Name(s)
    ursodiol

    10. Eligibility

    Sex
    All
    Maximum Age & Unit of Time
    5 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Biochemically proven peroxisomal disorder, including: Zellweger syndrome Pseudo-Zellweger syndrome Neonatal adrenoleukodystrophy Bifunctional enzyme deficiency Infantile Refsum's disease
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Kenneth Setchell
    Organizational Affiliation
    Children's Hospital Medical Center, Cincinnati
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Learn more about this trial

    Study of Bile Acids in Patients With Peroxisomal Disorders

    We'll reach out to this number within 24 hrs